New data show Symbicort reduces attacks in mild asthma when used as an anti-inflammatory reliever
Trial reflecting real-world practice showed a reduction in the rate of asthma attacks compared to the most commonly used reliever therapyNew data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol) as a potential anti-inflammatory reliever in mild asthma.1 These results are published in the New England Journal of Medicine and are being presented at the American Thoracic Society 2019 International Conference.1 The trial compared Symbicort Turbuhaler with two commonly used